Journal
PEDIATRIC BLOOD & CANCER
Volume 64, Issue 11, Pages -Publisher
WILEY
DOI: 10.1002/pbc.26594
Keywords
ALL; blinatumomab; lineage switch; MLL
Categories
Ask authors/readers for more resources
Blinatumomab is a bispecific T-cell engaging CD19 antibody used in refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL). Recently, lineage switch to a myeloid phenotype has been described following CD19 targeting treatment in three pediatric patients with mixed lineage leukemia (MLL) rearranged ALL. We report the case of a female who received blinatumomab for a first relapse of ALL without MLL alterations. She suffered from a second relapse early after hematopoietic stem cell transplantation and was treated with blinatumomab again. During this treatment, the leukemia lost CD19 expression as well as nearly all other B-cell markers, while still harboring the initial minimal residual disease marker, and switched to a myeloid phenotype.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available